Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | RAF1 | P04049 | 9/20 | 0.41 |
| ▸ | BRAF | P15056 | 7/20 | 0.41 |
| ▸ | LOX | P28300 | 2/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643556 | 0.84 | RAF1 (0.42) | KDRRAF1BRAFLOXLOXL2 | |
| SCHEMBL20292453 | 0.83 | BRAF (0.53) | KDRRAF1BRAFMETHDAC3 | |
| SCHEMBL177768 | 0.81 | RAF1 (0.55) | KDRRAF1BRAFHDAC3HDAC4 | |
| SCHEMBL619963 | 0.81 | RAF1 (0.57) | KDRRAF1BRAFMETEPHX2 | |
| SCHEMBL620468 | 0.78 | KDM4C (0.55) | — | |
| SCHEMBL16507708 | 0.78 | KDR (0.47) | KDRRAF1BRAFMETGSK3B | |
| SCHEMBL10163343 | 0.77 | RAF1 (0.76) | KDRRAF1BRAFMETHDAC3 | |
| SCHEMBL26921943 | 0.77 | HIF1A (0.53) | KDRBRAFMET | |
| SCHEMBL2889232 | 0.77 | KDR (0.52) | KDRRAF1BRAFMETGSK3B | |
| SCHEMBL16651380 | 0.76 | KDR (0.67) | KDRRAF1BRAFMETGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| US-8124630-B2 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124630-B2 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | RIEDL BERND (DE) | 2012-02-16 | — | — | US | disclosed |
| US-7928239-B2 | Anticarcinogenic agents | BAYER HEALTHCARE LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7897623-B2 | FDA Orange book listed patent for sorafenib tosylate; tablets | BAYER HEALTHCARE LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090118268-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | RIEDL BERND | 2009-05-07 | — | — | US | disclosed |
| US-7528255-B2 | Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528255-B2 | Hydroxy, ω-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080153823-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-06-26 | — | — | US | disclosed |
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-05-08 | — | — | US | disclosed |
| US-7351834-B1 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080032979-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors | BAYER HEALTHCARE LLC | 2008-02-07 | — | — | US | disclosed |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | BAYER HEALTHCARE LLC | 2008-01-31 | — | — | US | disclosed |
| US-7235576-B1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153823-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BRAF, RAF1, ARAF | KDR 567/4885RAF1 2/4885BRAF 1/4885 |
| US-20080108672-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors | BRAF, RAF1, ARAF | KDR 567/4885RAF1 2/4885BRAF 1/4885 |
| US-20080032979-A1 | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors | BRAF, NRAS, RAF1 | KDR 192/4885RAF1 3/4885BRAF 1/4885 |
| US-20080027061-A1 | omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors | MAPK1, MAPK8, MAPK3 | KDR 2141/4885RAF1 452/4885BRAF 344/4885 |
| US-20090118268-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | MAPK1, MAPK8, MAPK3 | KDR 2141/4885RAF1 452/4885BRAF 344/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDR 456/4885RAF1 2/4885BRAF 1/4885 |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, NRAS, RAF1 | KDR 558/4885RAF1 3/4885BRAF 1/4885 |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDR 567/4885RAF1 2/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.